Besides, the combination treatment with v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors and MEK inhibitors promotes GSDME cleavage and HMGB1 release in melanoma cells, which activate dendritic cells and ultimately lead to the proliferation of T cells to exert its anti-tumor effects (Erkes et al., 2020). Here, GSDME is linked to melanoma.